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'FHl2.J L'lO.LB OF ALDOSTERONE 
Lli TIHl!.; .PATHOGJ:!jl\l.t:.;0It) OF H.YJ:J1~RT'J:'jN/:::lIOH 
The high incidence and vast importance of high 
blood pressure in the causation of disease and death 
today are unquestioned. Hypertension is second only 
to arteriosclerosis as the disease with the greatest 
fatality rate, and accounts for over one-fifth of 
all deaths per year. (1) 
The exact incidence of hypertension as quoted 
by different investigators varies greatly. It has 
been variously computed as twenty million, fifteen 
million, and six million persons in the United states 
alone. This discrepancy is not due to error, but to 
varying criteria used in the selection of cases. 
Hypertension, either primary or secondary, occurs in 
five to twenty per cent of the total population, and 
its incidence rises to over fifty per cent in per-
sons over age fifty. 
The term hypertension connotes a systemic arte-
rial pressure consistently above the accepted normal 
values. These are customarily established as 140/90. 
However, many people today regard fixed criteria for 
diagnosis as no longer acceptable. True hypertension 
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implies an elevation in both systolic and diastolic 
blood pressures. Although it is possible for only 
the systolic pressure to be elevated, this systolic 
type of hypertension is etiologically distinct, and 
is a field separate from the realm of this thesis. 
Here only the true or diastolic hypertension will 
be considered. 
Hypertension has been variously classified by 
different investigators. Perhaps the most standard 
one is the classification w~~ch is reproduced below. 
Etiologic Classification of Hypertension 
I. Essential (or Primary) 
A. K . .uenlgn (incidence about ninety per cent) 
B. Malignant (incidence about ten per cent) 
II. Secondary 
A. Renal 
B. Endocrine 
C.Neurogenic 
D. Psychogenic 
E. Cardiovascular 
F. Miscellaneous 
When there is a persistent elevation of the systolic 
and diastolic blood pressures without a demonstrable 
cause, the condition is referred to as essential or 
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primary hypertension. This is subdivided into the 
benign or chronic phase, and the malignant or accel-
erated phase, depending on the rate of progression 
of the disease. Benign hypertension is character-
ized by a gradual and often insidious onset, slow 
progression, and long duration extending over ten 
to forty years. Malignant hypertension refers to 
the small per cent of cases (one to seven per cent) 
which progress rapidly and are characterized by high 
diastolic blood pressure, papilledema, progressive 
renal failure, and renal necrotizing arteriolitis 
at autopsy. (2) Some workers feel that this clas-
sification is incorrect, as they feel secondary 
hypertension may enter a malignant Dhase. This 
argument is beyond the scope of this thesis. 
It has been the goal of many investi ors 
througb the years to discover a morphological or 
biochemical abnormality which 'would act as a causa-
tive factor to expla the hypertensive phenomena 
now classified as es,sential hypertension. h 
increased knowledge of endocrinology, including the 
isolation, purification, and synthesis of adrenal 
cortical hormones, many vvorkers feel this is now 
possible. To investigate this possibility, this 
thesis is dedicated. 
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In 1952, Simpson and Tait (3) first showed that 
it was a new steroid which was responsible for tbe 
1 corticoid activity of the adrenals. Two 
years later, these same workers, in collaboration 
with Heichste , Wettstein, and their respective 
EsT-OUPS, discovered its chemical formula. This ITI.in-
eral corticoid was later named aldosterone. 
The chemical formula of aldosterone shows the 
important differentiat point between t s hormone 
Find cortiscne, hydrocortj.soDe, ane other steroids. 
(4) This is the "presence of an aldehyde in 
position eighteen. In solution, aldosterone is mainly 
in the form of a hemiacetal between C eleven and C 
eighteen, as shown above. 
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Aldosterone is the major mineral corticoid 
excreted by the adrenal cortex, but is not the only 
one. II-Desoxycorticosterone and dehydroepiandosterone 
are also mineral corticoids but hav2 leE3s IJ.orma.l 
siological activity than does aldosterone. Com-
parative bioassays have revealed that adrenal steroids 
may not act purely as gluco or mineral corticoids, 
but may have overlapping functional potencies. rrhe 
co.mparative act jon of aldosterone, hydrocortisone, 
and desoxycorticosterone are listed below. (5) 
.0f:./I' I1'vJ.i1il1b D 
HORl'V101~E GlJUOOCOldlICOID OBrICOID 
:::rydrocortisone 1 
Aldosterone 0.5 
1 
200-400 
DOC (Desoxycorticosterone) 0 25 
The functional zonation of the adrenal cortex 
has been established beyond any reasonable doubt. 
(6) The zona glomerulosa produces mostly mineral 
corticoids and is little affected b corticotropin, 
whereas the zona fasciculata an~ zona reticularis 
form predominately ~luco corticoids, 17-keto ster-
oids, and estrogens, and are dependent upon cor-
ticotropin for growth and secretory st~mulation. 
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Aldosterone is synthesized mainly by the enzy-
matic introduction. of an aldehyde group in the C 
eighteen methyl group in the d position. .Smaller 
amounts of aldosterone are synthesized tltrough other 
hways. Only the d form is biologically active. 
e is only very minimal binding in the plasma, 
and this is to albuIILin. 
The control of the secretion of aldosterone has 
not been completely elucidated. Several factors have 
been recognized as causing an increase in aldosterone 
secretion. (6) 
1. Reduction in intravasclJlar volume 
This reduction in intravascular volume as it occurs 
after sodium restriction, dehydration, or sma 
extravasation causes the greatest increase in secre-
tion--ten to forty-fold above normal. Converse 
overhydration with sodium chloride intakes of greater 
than 5 grams per day, or infusion of blood or albumin 
lead to a decrease in normal aldosterone secretion. 
Various baroreceptors in the carotid arteries and 
the right atrium have been implicated in the regu-
latioIl of these volume-induced changes, but these 
have not been proven. 
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2. Angiotension II 
Angi_otension II, the active COl!J .. ponent formed in 
renin may cause an increase in aldosterone secre-
tion. 
3. Adrenoglomerulotropin 
Adrenoglomerulotropin, a lipid factor extracted 
from the pineal gland, may increase a~dosterone 
secretion. 
4. Adrenocorticotropic hormone 
Pituitary corticotropin does increase aldosterone 
secretion in man, the rise is smaller than 
that sustained by other adrenal ster6ids, and is not 
prolonged. 
rrl'1e plJ.ysiologic ortance and effect of aldo-
sterone in man was not realized until 1955 when Conn 
described the ~:;~1Ddrome oJ a pota,sf3ilJJu los ;;; nephri-
tis which he called primary aldosteronism. (7) This 
is now known as Conn's syndrome. Clinically, this 
syndrome is characterized by paresthesias, intermit-
tent tetany, Dolyuria, polydipsia, severe periodic 
':Ne ss and Hparalyses ll , arterial hypertension, and 
a lack of edema. The biochemical laboratory data in 
such cases show an alkalosis with a pH greater than 
7.5, a lovv serum potassium (1.6-2.5 mEq. jL), and a 
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high serum sodium. The sweat, salivary, and urinary 
potassium values are lo~ whereas t se values for 
sodium are high. Pathologically there is usually 
an adrenocortical tumor (adenoma), or distinct 
adrenocortical hyperplasia. 
With the discovery of aldosterone and the iden-
tification of Conn's syndrome, it was not long until 
investigators were postulating the possible causa-
tion of cases of essential hypertension via the aldo-
sterone mechanism. rrhere were many presumptive 
evidences at that time which might have le d investi-
gators to such a hypothesis. 
Presumptive Evidences for this Helationship 
Such a hypothesis (that essential hypertension 
was caused by an excess production of aldosterone) 
could explain many already known clin:Lcal and exper:L-
mental observat:Lons. 
1. The hypertension in Cushing's syndrome 
and the hypotension in Addison's disease. 
2. The hypertension in the s:)rndrome of pri-
mary aldosteronis~. (Conn's syndrome) 
3. The correlation between the elevation of 
8 
blood pressure in patients, and their 
sodium chloride intake. (8) 
4. The benefical effect in a certain number 
of hypertensive patients of the rice diet 
(9, 10, 11) or diets limited to two hun-
dred and fifty mg. of sodium per day_ 
(12, 13, 14) 
5. The increased concentration of sodium in 
the muscles and arteries of patients with 
essentj_al hypertension, and of animals 
made hypertensive by various procedures. 
(15, 16) 
6. The hypertensive effect of desoxycorti-
costerone acetate in normal subjects and 
in Addisonians receiving a diet with normal 
amounts of sodium. (17, 18, 19, 20) The 
potentiating effect of salt on this DOCA 
pressor activity, (21, 22) and the dis-
appearance of this effect when sodium. 
chloride is removed from the diet. (22) 
7. The increase in the DOCA pressor effect 
in animals with decreased renal functional 
mass. (23) 
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8. The DOCA pressor effect in nephritic 
and hypertensive patients. (17, 24) 
9. The rise in blood pressure after an 
increase in dietary salt in hypertensive 
patients, (22) and the disturbance in 
salt and water excretion following sodium 
restriction. (25) 
10. The identical appearance of the capil-
laries of the bulbar conjunctiva in 
patients with essential hypertension and 
in patients with Cushing's syndrome. (26) 
11. The hypertrophy of the adrenal cortex, 
especially the zona glomerulosa after 
angiotensin administration in experimental 
renal hypertension. (28) 
12. The blood pressure fall in patients with 
essential hypertension following restric-
tion of dietary potassium. (29) 
13. The significant decrease in hypertension 
after complete removal of the adrenal cor-
tex in dogs and rats with acute or chronic 
. '1 h ' . (An 31 22') experlmen1Ja_ ,yper"t;enslon. \../v, ,) 
This evidence is, however, only pre sumpt iv'e • 
Before the validity of the hypothesi,s can be tested, 
concrete evidence must be obtained. 
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Evidence Substantiating this Hypothesis 
The most extensive investigations of the role 
of aldosterone have been made by Genest. (33). His 
work was be~un in 1948 when only the most basic work-
ing hypotheses were known, and measurements for sepa-
rating and measuring adrenocorticosteroids were very 
crude. These first studies used an aluminum oxide 
column for eluting the corticosteroid fraction of 
urine. With these methods he could detect no dif-
ference between the values obtained for h;y-pertensive 
patients with high sodium takes and high blood 
pressure levels, and these same patients during 
sodium restriction with blood pressure reduction to 
normotensive levels. 
After aldosterone was discovered in 1952 by 
Simpson and Tait, using the newest techniques of 
paper ch..romatography and the biological assay for 
sodium-retaining act ivi ty 'which they sugge sted, 
Genest was able to isolate the purified aldoster-
one fraction. When this fraction of the purified 
extract obtained from the urine of hypertensive 
patients was then injected into adrenalectomized 
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rats, a significant decrease (p is less than 0.001) 
in the urinary sodium potassium ratio could be seen, 
in co~parison with those rats which received injec-
tions of urine fraction extracts from normotensive 
patients. Thus this finding suggested first, in 
1956, that more aldosterone was excreted in the urine 
of hypertensive patients than of normotensive ones. 
(34) 
This method was soon found to lack specificity 
and accuracy, and in 1958, Genest reported studies 
on tbis problem using a nevv ph;)Tsico-chemical rnetbod 
of aldosterone determination. (35) With this he 
demonstrated a two-fold increasE ~ mean urinary 
aldosterone excretion in patients with essential, 
renal, and malignant hypertension, as conpared to 
normal subjects. 'I'his difference 'Nas statist ically 
significant with p less than 0.001. Also he demon-
strated an excessive daily variation in the aldos-
terone content of the urine of hypertensive patients. 
This was in marked contrast to the relatively stable 
excretion of aldosterone in normal subjects. He could 
find no reason to account for these variations--such 
as the nresence of acute stress, a chronic anxiety 
state, or tbe level of sodium or potassium intake. 
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In 1960 he completed two hundred forty-seven 
determinations of urinary aldosterone in one hundred 
forty-three normal sub,jects and hypertensive patients 
(36) In this study, patients with essential, renal, 
and. malignant hypertension shovved a two-fold to four-
fold increase in average urinary aldosterone excretion 
as compared to normotensive patients. Forty-three per 
cent of all aldosterone determination patients with 
essential and malignant hypertension were greater tb.an 
the upper normal limit (two to ten micrograms per " \ Gay) • 
In each of the th.ree grou~s the differences between 
the means were statistically significant. For essen-
tial hypertension as compared to normotension, p was 
less than 0.001. filor renal hypertensIon as compared 
to normotension, p was less than 0.005. For malig-
nant hypertension as compared to normotension, p 'Nas 
less than 0.001. 
These results are from spot determ tions on 
hypertensive patients. However, Genest realized that 
such determinations could not reflect the marked over-
lapping which might occur between normal and hyper-
tensive patients. For this reason he introduced a 
continuous study of the urinary aldosterone secretion 
of hypertensives and nOrl:Jals for periods of five to 
twenty consecutive days. In some cases the subjects 
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were placed on fixed sodi.um and potassium intake diets., 
while in others, the diets were self-selected. Normal 
subjects' daily urinary aldosterone excretion remained 
vvell IJljithin normal limits even when these subjects were 
undertaking their usual activities, and despite marked 
variations in dietary sodium intake. However, all of 
the hypertensives but one showed excess fluctuation of 
daily urinary aldosterone above normal range despite 
hospitalization. These fluctuations were more marked 
in the malignant phase of hypertension but were also 
:oresent in asymptomatic essential hypertension. No 
edema was present in these subjects. 
There are several plausible explanations for the 
wide fluctuations of urinary aldosterone nobed. s 
may be a variation in excretion rate, or an a era-
tion in the metabolic degradation of aldosterone and 
its consequent urinary excretion. Fluctuations may 
occur as a result of emotional disturbances. Increases 
have beerJ. obe,erved in medical students during exami-
nations when anxiety was nresent. (3'7) A.lso one 
should consider the fact that the adrenal glands of 
hypertensive patients might be more respon,sive to 
adrenocorticotropic hormone. This possibility may 
be considered rather unlikely, due to the fact that 
ACTH' is thought by most observers to have only a 
slight tropic action on aldosterone. 
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Genest's results wit:1. essential hypertension 
were confirmed by Garst. (38) She initiated a 
study whose primary aim was to determine the inci-
dence of aldosteronism in ll;rpertensive 1)atients. In 
this statistically well-documented study she found 
that about twenty-five per cent of the patients with 
essential hypertension had significantly elevated 
levels of urinary aldosterone, using a paper chro-
ma1Jography method for determination. In none of 
these patients, however, were the abnormal serum 
electrolyte changes seen such as occur in primary 
aldosteronism. 
Venning (39) studied aldosterone in hyperten-
sives by a similar method with special emphasis on 
aldosterone changes as correlated with specific 
etiologies. She found tha~ although the majority 
of the patients vvith essential hypertex1sion on a 
normal sodium diet excrete(l amounts of aldosterone 
within normal range, the mean value was statisti-
cally significantly higher than that seen in normo-
tensive patients. She noticed also that most of the 
hY1)ertensive patients were in an older age than the 
normotensive ones. The effect of age on aldosterone 
excretion is not kn0i\!1l., but if it declines with 
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advancing years as does the excretion of the other 
adrenal hormones--17-hydroxycorticoids and 17-
ketosteroids--the difference between the two groups 
would be even greater. 
SbB noticed that WbBD renal disease was a 
secondary complication of essential hypertension, 
the mean value of aldosterone excret j~on was higher, 
even though the iD~ividual values were still within 
normal limits. But, if the hypertension were due to 
primary renal disease, the aldosterone excretion values 
were beyond normal range. 
In addition to studying the physiologic effects 
of aldosterone, Genest studied its relationship to 
another normally occurring steroid, pregnanetriol. 
(Pregnane 3a, 17a, 20a-triol) This steroid is derived 
mainly from prossesterone after 17-hydroxylat iOD.. Sev-
eral authors (40, 41) feel that progesterone is an 
aldosteroD.e antagonist because it inhibits the sodium 
retaining effect of aldosterone. Therefore, in h~rper­
tensives one might expect tb.G pregnanetriol values to 
be decreased. Genest found a highly significant 
decrease (p is less than 0.001) in average preg-
nanetriol excretion values for essential, renal, and 
malignant hypertension patients as compared with nor-
mal subjects. Similar results were obtained by 
Bongiovanni and Eberle (42) 
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The ratio of pregnanetriol to aldosterone has 
been proposed by Genest as an even more sensitive 
index of cardiovascular disease. This is true, he 
feels, whether there is an absolute increase in 
aldosterone, or a relative increase over a decreased 
progesterone. This ratio all three groups of 
hypertensive patients is below the lo\ver lim.its of 
normal range in ninety-two per cent of all patients 
studied in this regard. 
Since the excretion of pregnanetriol is seem-
ingly affected by the presence of b,)Tpertension, one 
:ni,:;;ht expect that other steroi::,! val ues would also 
be affected. However, Genest has found no differ-
ence in tb~ mean excretion of cortisol, cortisone, 
and their tetrahydro derivati\Tes, etiocholanolone, 
and the tetrahydro derivative of l'7-hydroxyl, 11-
desoxycorticosterone in patients with hypertensi.on--
essential, renal, or malignant--and normal subjects. 
The higher tharl usual excretion rates in hyper-
tensive patients with associated renal disease seem 
to indicate a possible renal-adrenal interulay in 
this disease. This uossibility has been variously 
considered in the medical literature since 1934, 
when Goldblatt and his colleagues uroduced hypertension 
1'7 
experimentally in animals by clamp the renal 
arter~51. (43) Their findings, and later work by 
Houssay and Fasciolo of Buenos Aires, suggested that 
a h1.1IDOral substance might be responsible for such an 
elevation. This substance was later isolated and 
found to be renin, an enzyme ch reacted on a sub-
strate in nlasma to nroduce a vasoactive substance. ~ l 
(It is interest to note that in 1898, Tigerstedt 
and Bergman of Stockhold first demonstrated the nres-~ L 
ence of a humeral substance in the kidney. This sub-
stance had remained dormant for thirty-six years until 
Goldblatt attempted his classical experiment.) 
This vasoactive substance was named variously 
hypertensin and angiotonino To avoid this confusion 
in names, the name angiotensin I has been accepted 
for this substrate. (44) Angiotensin I is a poly-
peptide. A converting enzyme, also present in the 
blood, breaks off two terminal amino acids to form 
angiotensin II--an extremely potent octapeptide 
vasoconstrictor. This substance bas been shown to 
be ten times as vasoconstrictive as I-epinephrine. 
(45) 
Cl:he exact nature of this renal-adrenal interplay 
has not yet been completely elucidated. However, it 
has been shown (46, 47) that renin infusion in dogs 
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producing experimental hypertension, will increase 
the rate of aldosterone secretion. Carpenter, Davis, 
and Avers have shown that the infusion of renin into 
- " 
hypophysectomized-nephrectomized dogs will increase 
not only aldosterone, but also corticosterone. Like-
wise, the infusion of synthetic angiotensin II into 
similar dogs has been shown to increase both of these 
steroids. In fact, with doses of angiotensin II too 
small to elicit a blood pressure response, physio-
logically significant increases in aldosterone secre-
tion were occasionally observed. Whereas dogs 
vilith benign hypertension the kidney renin content was 
only slightly increased and aldosterone secretion was 
within normal limits, in dogs with malignant hyper-
tension, there was a ten-fold increase in renin con-
tent of the kidneys and aldosterone output was markedly 
increased. 
Hardy and his colleagues report the case of a 
fourteen year old girl with marked hypertension asso-
ciatedwith renal artery muscular hypertroDhy. An 
adrenal vein blood sample prior to nephrectomy (which 
abolished the h~fPertension) showed a markedly elevated 
aldosterone content which was statistically signifi-
cant as compared with that of nonhypertensive patients 
undergoing laparotomy. Postoperatively, the urinary 
19 
aldosterone was less than half of the value obtained 
preoperatively. They hYDothesize that the renal 
• 1 • • +-,. lSCDemla ln uTI1S case was res sible for the pro-
duct ion of the increased aldosterone levels via a 
renin-angiotensin type mechanism. 
Genest has also studied extensively the renal-
adrenal relationships. (33, 49) His experiments 
consisted of acute and long-term intravenous infu-
si:J s of synthetic angiotensin, which is identical 
to that isolated from oxen, except that the aspartic 
acid is replaced by asparagine in the synthetic 
material. In these experiments he studied urine 
volum.e, sodium and potassium excretion, glomerular 
filtration rate as approximately measured by cre-
atinine clearance, urinary aldosterone, cortisol, 
cortisone, and their tetrah;ydro derivatives, in both 
normotensive and essential hypertensive individuals 
maintained on fixecl sodium and potassium intakes. 
His results are summarized below. 
I. Effects of Angiotensin on Urinary ectro-
lytes and Creatinine Clearance (An~iotensin 
administered at rates to produce an increase 
of ei teen to thirty millimeters of mercury 
diastolic pressure above control levels) 
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A. Results in Normal Subjects 
1. rked sodiu.m retention but with 
decrease in both sodium and potassium 
excretioYl. 
2. Decrease in urinary sodilJJTI potassium 
rat io. 
3. Creatinine clearance variable. (Thus 
the decrease sodj.um and T)otassium 
excretion can occur without change in 
glomerular filtration rate.) 
B. Results in Hyperten~3ive Subjects 
1. TiHarked sod ium excretion but with 
increase in both sodium and potassium 
excretion. 
2. Increase inLJ.rinary sodium potassium 
ratio. 
Increase in creatinine clearance. (Too 
few patients to be too signific .) 
II. Effects of Angiotensin on Aldosterone and 
Otber Corticosteriods. (Angiotensin admin-
istered at rates to increase diastolic pres-
sure fifteen to thirty-five millimeters of 
rilercury above control levels.) 
A. Results in Normal Sub;iects 
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1. Two and one-half to eleven-fold increase 
in urinary aldosterone. 
2. Parallel rise in aldosterone's reduced 
metabolite, tetrahydroaldosterone. 
3. In two of four -patients, a two to three-
fold rise in urirlary cortisol ane] tetra-
hydrocortisone. (A rise of this magni-
tude is small in terms of physiologic 
si ificance in comparison to the rise 
of aldosterone.) 
It is interesting that in two cases where ang10-
tens was infused at low levels where the effect was 
still subhypertensive, there was a signi cant degree 
of aldosteronuria. This appears to indicate the great 
sensitivity of the aldosterone response to angiotensin. 
Control infusions of five per cent glucose, epinephrine, 
norepinephrine, and phenylephrine were administered to 
these natients to see if the increased urinary aldo-
sterone was , 1 lJ ne result of the stre~:s of the ion 
experiment. In all cases exc one, the aldosterone 
level did not undergo any Sl ificant change. (In 
one instance th phenylephri~e, there was a small 
rise, but t c was quite small in comparison to that 
obtained during the infusion of angiotensin.) Venning 
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(50) has shown an incrsase in urinary aldosterone 
duri emot i onal stres s s 1 t ua t j ons. 'T'he se exper1-
ments show that th1s increase 1n aldosterone in such 
s1tuat1ons is not med1ated through catecholamines. 
B. Results 1n Ben1gn Hypertens1ve Patients 
1. Increase 1n urinary aldosterone. 
These stud1es g1ve strong clin1cal support to 
the renal-adrenal hypothesis and seem to correlate 
well with the experimental studies of Tobian (51) 
which link the granulations of the renal juxta-
omerular cells to the adrenal zona glome osa and 
sodill.m re lation. He feels that the w1dth of the 
zO::Ja omerulosa, ch secretes aldosterone, thB 
gran1Jlarity of the renal juxtaglomeru.lar cells, ch 
'"' ' DrOuao secrete renin, and thB renin content of the 
kidney vary in parallel. They increase In reSDonse 
to low sodium intake, or high renal art ·pressure 
such as seen in cases of hypertension and after admini-
stration of renin or desoxycorticosterone. 
The angiotensin studies of Genest do not solve 
all problems, however. In particular they do not 
explain why the increased aldosterone levels during 
angiotensin 1nfusions in normal patients are accom-
Danied by marked sodium restriction and lowering of 
the urinary sodium potassium ratio; whereas in patients 
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with hypertension, these same aldosterone increases 
are accompanied by marked decreases in the urinary 
sodium potassium ratio. rrhis appears to st a 
basic difference between normal subjects and hyper-
tensive subjects in response to angiotensin. 
Selye, (23) in 1942, was tbe first to experi-
mentally produce nephrosclerosis t ougb the use of 
desoxycorticosterone acetate. s first experiments 
were in chicks, but later similar findings were obtained 
in the dog, rat, and monkey. In 1943 he repeated his 
experiments in rats, and also dete d" that thi.s 
experimentally induced renal disease would be accom-
panied by a rise in blood nressure and structural 
changes in the systemic blood vessels such as those 
seen. in the malignant hypertensive patient. He noted 
that this was particularly pronounced ~hen the rats 
were kept on a higb sodium chloride diet. 
s presumptive evidence of the effect of a 
mineral corticoid has been repe~ted using aldoster-
one by Gross. (55) He found that aldosterone, if 
given in relatively higber amounts than DOCA, WOl}ld 
nroduce a comparable increase in blood pressure in 
rats. However, it did not produce the severe renal 
lesions which Selye and Gross both observed with 
24 
DOCA. This, then, is strong eXDerimental proof of 
the effect of aldosterone in an experimental animal. 
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Evidence ]\Jot Substantiating This Hypothesis 
In a suO.iect whi.ch is exceedingly complex, and 
in which there are many different factors occurring, 
it is inevitable that there should not be unanimity 
of opinion between various authors. This is cer-
tainly true of this field. 
Laragh (53) and his group in 1960 completed a 
study of the secretion of aldosterone in hypertension. 
His method of analyzing the aldosterone content was 
entirely different from that of Genest. In this 
methDd he utilized the technique of radioactive iso-
tope dilution. This involved the injection of a 
tracer of tritium labeled aldosterone, and the deter-
mination of the specific activity of its m~tab01ite, 
tetrahydroaldosterone in the subsequent twenty-four 
hour urine. The difference between the specific 
activity of the injected tracer and that of the uri-
nary metabolite is a measure of the endogenous contri-
bution. This permits estimation of the actual daily 
secretion of aldosterone, thus obviat , he feels, 
the inherent diff.icul ty in studies which have been 
based on mEasurement of the small fraction of aldo-
sterone excreted unchanged in the urine. By this 
technique normal subjects produce one hundred-fifty 
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to tl'xee hundred-fifty lDlcrograms of aldosterone per 
day, and this value may rise to one thousand micro-
grams per day with sodium deprivation. However, feed-
ing of excess sodium can suppress the normal a160-
sterone secretion to as low as fifty crograms per 
day. 
In this study he classifies hypertensives in 
three groups--( 1) primary hypertension, whicJ'l repre-
sents patients with benign essential hypertension, 
(2) advanced hypertension, which includes those 
patients with either nitrogen retention or retinal 
hemorrb.ages, and (3) malignant hypertension, il1Nhich 
the patients had papilledema. He found that in patients 
with benign hypertension, the rate of aldosterone 
secretion was normal. In addition, these patients 
res ed normally to sodium depreivation by increas-
ing the aldosterone secretion. However, also fmJ.nd 
that in patients 'lvith primary hypertension, as in nor-
s, increased aldosterone secretion is not neces-
sary for normal sodium conservation. In addition, 
both of these groups showed that the Dlasma potassium, 
or the state of potassium balanc~ is an important stimu-
lus to aldosterone secretion. This might account for 
the increased excretion ascribed to sodium or volume 
changes in other studies. 
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In contrast to patients with benign h;ypertenE.iion, 
those 'vvith malignant hypertension shovved defir1ite 
increases in the aldosterone secretion rate. These 
\Tcl.l1}8S d from six hundred to ten thousand micro-
grams per day. At autop , the adrenal B.nds of these 
patients were at or above the upper 1 its of normal 
in we Thus, these patients d fer from patients 
with primary aldosteronism not only in their clinical 
features, but also in that in no instance has an adre-
nal adenoma been discovered. These patients further 
differed from those with benign hypertenf3ion in that 
var tions in the sodium intake did not modify the 
aldosterone secretion rate. However, in these sub-
jects as well as normals, the aldosterone secretion 
rate was related to potassium balance. 
In addition to these studies, measured 
the aldosterone secretion rates of patients with Conn's 
syndrome. In these cases, aldosterone values ranged 
from five hundred ten to sixteen hundred ninety micro-
grams per day. 'llhus, in both malignant hypertension 
and primary aldosteronism were excessive high value s 
obtained. Laragh concludes that this hypersecretion 
of aldosterone might be a secondary or a cOllcomi tant 
uhenomenon. However, the possibility that aldosterone 
might be of causal significance cannot be excluded. 
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ThB most damaging cr icism of the work of Genest 
was written by Cope (54) in 1962. He accepts tbB fact 
as stated by Genest that subjects with essential or 
mali t hypertension have a tendency to excrete sig-
nificantly more aldosterone than do normal subjects. 
However, he cautions aga t drawing the conclusion 
from these observations that there is necessarily any 
etiological relationship between the two. 
He hypothesizes several Dossible exnlanations. 
fj~here might be an alteration in renal physiology in 
patients with hypertension, whereby aldosterone is 
excreted more readily from the blood into t.he urine, 
for vvith Genest I s techniques, the relationship between 
blood levels and urinary excretion is unknown. Or, 
he hypothesi",es, there m be a change the extent 
to which aldosterone bound to a plasma protein, thus 
producing a similar situation. Although methods are 
not yet available to estimate the excessively small 
concentration of aldosterone found in plasma, and thus 
answer these questions, the newly available isotopic 
labeled aldosterone has made possible t measurement 
of aldosterone secretion rates. Such a measurement 
was atte ed by Laragh and the re suIt 8 reT)orted earlier 
in this paper. Cope has repeated these studies. The 
isotope dilution effect makes it possible to estimate 
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the total quantity of aldosterone metabolites in the 
ur e, even if many of them are unknown nature. 
This study, in contrast to the one of Laragh, 
took cognizance of the fact that patients with severe 
renal impairment have a delayed renal excretion of the 
trit labeled aldosterone. This delayed renal excre-
tion provides opportllnities for proportionately larger 
el ination bv non-renal routes (ie. feces), in which 
the radioactive metabolite cannot be detected. To 
correct for this fact, a mathematical formula was 
devised and used i~ his series. 
Cope found that for l10rmotensive patients, the 
rate of aldosterone secretion was sixty-two to two 
hundred seventy-five micrograms per day, with a mean 
secretion rate of one hundred forty-three micrograms 
per day. Por hypertensive patients of mixed etiology, 
the rates varied from thirty-one to eight hundred 
thirt,y-t';No micrograms per day , with a mean va of 
two hundred twenty-seven micrograms per day. However, 
he feels that the wide scatter of VallJeS (e cases 
above tvvo hundred, five below sixty) make the mean 
value of little significance. Thus, although in some 
cases the aldosterone secretion rates are above normal, 
the series also contains those with rates below normal. 
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After subdividin~ his cases accordi to patho-
sis, he finds that of seven cases .h essential 
hypertension, the rates varied from fifty-three to 
one hundred sixty-three micrograms DeJ::' day, vvith a 
mean value of one h1L."1dred seven micrograms per day. 
These fincH s are in agreement with Laragh, in that 
thB aldosterone secretion rates are not raised in 
t " 1 h t " essen 1a _yper enS10n. Of nine patients with a 
normal pyelogram, the mean secretion rate was two 
hundred thirty-five microgram.s per cJay ,I.vi th a range 
of forty-t'l'lO to eight hundred thirty-tvlTo micrograms 
per day. ~or nine patients with abnormal pyelo 
mean secretion rate was one hundred eight;y-six 
micrograms per day, with a range of thirty-one to 
foUl: hundred ninety-eight micrograms per day. In 
view of this wide scatter, the difference is of no 
significance. Of four patient,s with malignant 
hypertension, two had high secretion rates, while 
two were subnormal. Thtls, very high secretion rates 
are by no means invariable in malignant hypertension. 
In addition, his study included control patients 
who did not have hypertension, b-u.twere ill in vari-
ous ways. It is known that many patients with severe 
hype ension are ill in various ways other than \fi}ith 
hypertension. ThUS, it is desirable to compare 
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hypertensive subjects with other ill persons who 
differ essentially only in that they are normotensive. 
None of these ill normotensive patients had fever or 
any malignant disease, and in none was there any detect-
able degree of sodium depletion due to disease of 
natriuretic drugs. In these control patients the 
range of secretion was found to be fifty-six to six 
hundred four micrograms per day, vIi th a mean value of 
two hundred nine micrograms DeI' day. It is seen, 
refore, that tbBre is a de e of correla-
tion between the secretion rates of aldosterone in 
these two groups. 
From these extensive studies Cope concluded that 
a raised aldosterone secretion rate will be encoun-
tered in hypertensive sub,j ects in about one-third of 
the cases. The range of values is much greater than 
that seen in normals. But, in comparison to otbBr 
ill normotensive patients, no detectable d ferences 
can be seen--neither ln ranse of values or mean 
secretion e. 
From these conclusions Cope makes three gen-
eralizations: 
1. Patients th uncomplicated essential 
hypertension have aldosterone secretion rates within 
normal range. 
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2. Patients with malignant h~rpertension may 
have greatly elevated aldosterone secretion rates, 
but do not always. 
3. Hypertensive patients vJith an abnormal 
nyelogram are no more likely to show raised aldo-
sterone secretion rates than those 
pyelogram. 
h a normal 
Thus, these conclusions suggest that the fac-
tors these studies are not the ones wbich deter-
ne whe er aldosterone secretion is raised or not. 
It appears, thBrefore, that some determining factor 
or factors must be acting independent of the etio-
logi.cal classificat ion of the hypertensive condit ion. 
He feels the nature of such factors can only be specu-
lated upon. However, these studies seem to indicate 
that many t:v-pes of metabolic derangement can increase 
aldosterone secretion, just as many types of stress 
can increase cortisol production. And, since the 
comparison of aldosterone secretion in normotensive 
metabolic disorders to hypertensives is so similar, 
seems suggestive that at least some of the etio-
logical factors acting in the normotensive group are 
also operating in the hypertensive group. Thus, some 
of the aldosterone overproduction seen hypertensives 
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might be incidental manifestations of associated 
metabolic disturbances. 
He states, "it seems most improbable that a 
mild chronic overproduction of aldosterone is con-
cerned in the pathogenesis of essential hYPertension 
as suggested by Genest, for neither Laragh nor we have 
found any evidence of raised aldosterone production 
in essential hypertens ion. Iv10reover, Genest has 
shown that angiotensin acts as a stimulant to aldo-
sterone production even in doses too small to uro-
duce detectable hypertension. This claim, therefore, 
suggests that raised aldosterone secretion should be 
a sensitive indicator of circulating angiotensin--
more sensitive indeed than the blood pressure itself.1I 
(5Lj-) This is very doubtful, and can only be det er-
mined when plasma angiotensin levels can be easily 
ascertained. There is no reason to think that angio-
tensin is the only stimulus to aldosterone production. 
Genest has also suggested that the aldosterone 
levels may be only intermittently raised in hyper-
tensive studies, thus explaining why spot tests 
of secretion rate may not reveal tb~s rise. Cope 
feels there is little evidence to support this assujJ~p­
tion. He also presents additional evidence against 
the role of aldosterone in the causation of hypertension. 
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He relates that chlorothiazide and other like 
natriuretics often stimulate increases in aldo-
sterone excretion as sodium is lost. However, in 
these cases, the blood pressure falls rather than 
rises. 
There are other factors which seem to be unfa-
vorable to the basic asslJ.mption of the importance 
of the role of aldosterone in the pathogenesis of 
hypertension. It is well known that the highest 
values of aldosterone secretion occur in conditions 
other than hypertension. Dr. Ralph Peterson has 
found values up to three thousand micrograms per day 
in the states of cirrhosis and heart failure. Luetscher 
(55) and his group confirm these findings of very 
~igh aldosterone levels in conditions of ascites, 
rena}, and hepatic failure. Gross (56) points out 
that one of the most famous examples of increased 
aldosterone secretion is in a normal pregnancy. This 
is not due to an increased production of aldosterone, 
but a changed metabolism. And, in normal pregnancy, 
the blood pressure remains normal. However, in 
toxemia of pregnancy, when the blood pressure is 
elevated, the same values are seen as in a normal 
pregnancy. 
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The well-taught fact that aldosterone is inde-
pendent of pituitary control cannot be stated too 
dogmatically. Several author~ including Venning 
(57) and her colleagues, have found significant 
increases in the excretion of aldosterone after admini-
stration of ACTIL Venning's work suggested that ACTH 
may act synergistically with a specific aldosterone 
stimulating factor to enhance the secretion of aldo-
sterone. These observations sug~est caution in inter-
preting aldosterone secretion rates in stressful situ-
ations. This effect is much less important than in 
the synthesis of glucocorticoids. 
Dawson (58) and his group attack tb~ basic pro-
blem from a different standpoint. He reasons that if 
aldosterone hypersecretion does influence malignant 
hypertension, it m"'ght be expected that an 
tion of aldosterone secretion should lower the blood 
nressure in these patients. Such an inhibition can 
be achieved by the administration of SU 4885, which 
blocks the II-hydroxylation step in the biosynthesis. 
The use of this drug was first renorted by Jenkins 
( ro' - b" ))) and ... ~lS group. In hi dosages this causes a 
seneral suppression of steroid biosynt sis. In addi-
tion, the metabolic excretion product, tetrahydro-
desoxycorticosterone, also having mineral corticoid 
properties, is similarly blocked. 
In this study a thirty-seven year old male with 
malignant hypertension was treated with f;U 4885 and 
~rednisone. Prednisone was to act as a replacement 
for the glocucorticoids suopressed. In this patient, 
the institution of therapy was associated with an 
increased rate of urine sodium and chloride excre-
tion, a fall in serum sodium, a',d a se in serum 
potassium. Dur the treatment the aldosterone excre-
tion 11 to minimally detectable rates. ACTH test 
performed during the treatment showed marked adrenal 
irment w very low cortisol levels. However, 
there was no significant change in the patient's blood 
pressure nor any improvement in his symptoms. These 
studies suggest that aldosterone hypersecretion is not 
the cause of, or the primary event in the pathogenesis 
of malignant hypertension. 
Hollander and Chabonian (60) exp n t increased 
aldosterone found in malignant hype ension Ilia another 
method. They have found that patients with primary 
Idoste:::'onism and patients with malignant hyperten-
sion have s icant increases in total exchangeable 
:zr 
sod.1u..1J, as determined by the 8)/04 space. Normal con-
troIs and patients with essential hypertension dtd not 
have thBse findin , although the pattent with benign 
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hypertension in congestive failure did. Also, these 
investigators noticed that the total exchangeable 
potas lum space was decreased severely in patients 
with prlmary eldosteronism, but on slightly decreased 
in patients with malignant hypertension. They pos-
tulate that the increase in sodium and extracellular 
fluid volume may be manifestations of a state of 
precoIJgestive heart failure, and this state may be 
responsible for the increased aldosterone excretion 
seen. 
Not all lnvestigators have been able to nrodu6e 
hypertension in experlmental situatlowby thE admini-
stration of aldosterone. It ls lnteresting to note 
that In patlents with Addison's disease, treatment 
wlth large doses of aldosterone normalizes the blood 
pressure, but does not cause hYTJertension. Gross (61) 
obserV'2d hynertension in rats sensitized by unilateral 
nephrectomy only when he injected five hundred mlcro-
grams of dl-aldosterone dally for four weeks. However, 
Gaunt noted no slgns of hypertension in intact rats 
when administering the same dose over seven months. 
In man, Thorn (62) has found that a dose of six thou-
sand micrograms of aldosterone daily provokes a rise 
blood pressure of only ten to twenty-two milli-
meters of mercury. 
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warter (63) and his co-workers feel that aldo-
sterone may provoke hypertension only in the presence 
of renal lesions. They suggest, also, that there 
may be great differences in sensitivity of the renal 
tublJleEJ to aldosterone in hypertensive pa tient s. They 
cite the example of one hypertensive pa-Gient in which 
the administration of one thousand micrograms of aldo-
sterone for three days had no noticeable effect on 
either blood pressure or electrolyte balance. 
Perhaps the most s ificant evidence against 
the role of aldosterone in the pathogenesis of hyper-
tension can be found in the report of Bar~ter (64) 
in 1962. In this .report he described three cases of 
a new clinical syndrome, hyperaldosteronism and hypo-
kalemic alkalosis viithout hypertension. CJ:1hese patients 
were examined because of varied, nonspecific reasons, 
and were found to have four important aspectf3 in com-
n~on. -Each had a hypokalemic alkalosis vvith potas-
sium values of 1.2 -2.3 mEq/L. Each had an elevated 
aldosterone level--up to seven hlJ_ndred fifty mjcro-
grams Der day, but none of these patients had elevated 
blood pressures after many readings and an extensive 
study. Because of the hyperaldosteronism, each patient 
had a kidney biopsy which revealed a unique lesion of 
the juxtaglomerular aI)paratus. This lesion consisted 
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of hypertrophy of the juxtaglornerular apparatue, which, 
from fixed preparations appeared to comprise four stages: 
1. hypertrophy of tl1e macula densa 
2. thickening of the juxtaglomerular cells with 
hyperplasia of the juxtaglomerular apparatus 
3. hyperchromatism of the vascular wall of part 
of the glomerulus 
4. ai!t0phy of the glomerulus 
II'he de"veloJ)ment of h;vpo}-;:alemia vvas associ,:~.ted 
with urinary loss of potassium in excess of intake. 
This loss was decreased but not prevented by restric-
tion of sod ium intake. It was also nrevented bv the 
"_ u 
infusion of serum albumin (which decreased the uri-
nary sodium to zero) and aldosterone antagonists. 
The blood pressure remained normal, even when the 
extravascular snaces were expanded with albmnin, so 
the absence of hYTlsrtensioIl cannot be attrib"Llted to 
hypovol a. 
The lesions of the juxtaglomerular apparatus 
su::;gest a l:t,ypersecretion of renin which should lead 
to hypertension. In addition, these patients on 
bioass showed increased amounts of a pressor agent 
resembl angiotensin in the sermIl. There lS little 
reason to believe that aldosteronism or the resulting 
potassium depletion produced the renal lesion, since 
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simi lesions have not been found 1n patients with 
primary or secondary aldosteronism, or in t kidneys 
of potassium-depleted rats. In fact, administration 
of aldosterone or meA to rats on average or 11.igh 
sodium diets causes a decrease in the prominence of 
the ,luxt omerular apparatus, and a decrease in the 
-renin content of the kidney. It is ssible also that 
the aldosteronism and the j1Lxtaglomerular apparatus 
lesion are both results of an lli'1identified coml:~on 
cause. However, it is more likely that the renal 
lesion should have d to the adrenalone. 
Although available evidence does not make a 
def ite explanation possible in this syndrome, 
Bartter has proposed a working hypothesis. In nor-
mal patients, he feels that angiotensin II, after 
its production via renin, has three functions: (1) 
a direct effect of blood pressure, (2) retention of 
sodium-via the kidney, and (3) stimulation of aldo-
sterone secretion. Normally, some function of blood 
pre s ,sure or se acts asa negative feedback to inhi-
bit renin production. However, he suggests that in 
these patients, for reasons unknown, there is a pri-
mary impairment in the vascular response to angio-
tensin. This results in a decreased in11ibition of 
renin production, therefore increased production of 
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renin, iotensin I, angiotens , and an increase 
in aldosterone secretion. He hypothesL'>es that in 
tbese cases, even though the angiotensin II is Unable 
to duce hypertension due to the primary defect, it 
might still stimulate the adrenal cortex to tbB over-
nroduction of aldosterone. 
Cope (54) attempts to explain raised aldosterone 
secretions encountered in some hypertensive subjects 
by nostulatin~ that there must be some other aspect 
of illness rather than the hypertension which is the 
determin g factor. He states that Laragh (53) and 
his group had observed that there was no apparent 
relation between the hei~ht of t blood pressure and 
the increased secretion rates of aldosterone which he 
found. However, Laragh cUd notice that in 1, 
the hypersecretion of aldosterone was more ilnpresE3ive 
in the seriously ill patients. Other investigators 
have noted similar phenomena. Venning (65) noted an 
increased urinary excretion of aldosterone and tetra-
hydroaldosterone in hypertensives when the general 
condition was deteriorating. Llaurado (60) has shown 
an increased urinary excretion of aldosterone due to 
a non-specific disturbance such as a surgical opera-
tion. Laragh (61) feels also that increased aldoster-
one secretion may be seen in essential hypertension 
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patients as renal or caEliac complications develop. 
Cope agrees with this general thesis, and feels when 
increased aldosterone secretion occurs in essential 
hypertension, it is probably due to a complicating 
factor. He feels this is probably also true in 
malignant hypertension. 
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BUlVIMARY 
1. The scope of the problem of hypertension is 
discussed, and a classification stated. 
2. The physiologic and chemical properties of 
aldosterone are presented. 
3. Presumptive evidences for the relationship of 
aldosterone to hypertension are Etated. 
4. The body of the thesis is used to present 
affirmative and negative evidence in regard to 
a basic hypothesis--that aldosteron.e is an etio-
logic agent in hypertension. Included in this 
evidence are views of various investigators 
as to aldosterone urinary excretion studies, 
experimental production of hypertension, and a 
new syndrome of hyperaldosteronism and hypo-
kalemic alkalosis without h;ypertension. 
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It is difficult to reconcile the differing 
results obtained by separate investigators in study-
ing the same aspects of a given problem, unless one 
considers differences in techniques and methods used. 
The major differences in opinion as to the urinary 
excretion of aldosterone as presented in this thesis 
are represented by Genest and Garst on one hand, and 
Laragh and Cope on the other. These must be inter-
preted in this manner. Whereas the former investi-
gators used a paper chromatographic method in their 
findings of an increased urinary excretion of aldo-
sterone in hypertensives (and implied from this an 
increased secretion), the latter men used a radio-
active isotonic dilution technique in their finding 
of no increased secretion of aldosterone in hyper-
tension. Although it is not possible to be dogmatic 
on this point, is appears most logical that the 
radioactive isotopic dilution method would be the 
more accurate. 
It would be false for one to say that there is 
not a large body of presumptive evidence which tends 
to associate increased aldosterone levels with essen-
tial hypertension. However, this presumptive evidence 
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of association is m.uch different from true concrete 
evidence of causation. The recently described syn-
drome of hyperaldosteronis:n without hypertension does 
much in negating such presumptive evidence. 
~or these reasons, this author must, in conclu-
sion, agree with Cope, that hyperaldosteronism is 
not a causative factor in either essential, renal, 
or malignant hypertension, but its frequent presence 
in such cases is probably due to secondary compli-
cating factors, the exact nature of which is not 
yet known. 
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